• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti-CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study.

作者信息

Rovin Brad H, Boxhammer Rainer, Thakur Anjali, Ronco Pierre M

机构信息

The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

MorphoSys AG, Planegg, Germany.

出版信息

Kidney Int Rep. 2022 Sep;7(9):2086-2090. doi: 10.1016/j.ekir.2022.05.031. Epub 2022 Jun 10.

DOI:10.1016/j.ekir.2022.05.031
PMID:35702397
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9186646/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6873/9459074/08935268717b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6873/9459074/08935268717b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6873/9459074/08935268717b/gr1.jpg

相似文献

1
Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti-CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study.接受抗CD38单克隆抗体非扎妥昔单抗治疗的膜性肾病患者接种新冠疫苗后的免疫反应：1b/2a期M-PLACE研究结果
Kidney Int Rep. 2022 Sep;7(9):2086-2090. doi: 10.1016/j.ekir.2022.05.031. Epub 2022 Jun 10.
2
Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy.评估非扎妥单抗在抗磷脂酶A2受体自身抗体阳性原发性膜性肾病中的安全性和有效性的1b/2a期研究
Kidney Int Rep. 2024 Jun 20;9(9):2635-2647. doi: 10.1016/j.ekir.2024.06.018. eCollection 2024 Sep.
3
Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.单克隆 CD38 抗体 felzartamab 在晚期抗体介导的肾移植排斥反应中的安全性、耐受性和疗效：一项 2 期试验的研究方案。
Trials. 2022 Apr 8;23(1):270. doi: 10.1186/s13063-022-06198-9.
4
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.新型抗CD38单克隆抗体MOR202用于复发或难治性多发性骨髓瘤患者：一项首次人体、多中心、1-2a期试验
Lancet Haematol. 2020 May;7(5):e381-e394. doi: 10.1016/S2352-3026(19)30249-2. Epub 2020 Mar 11.
5
Future landscape for the management of membranous nephropathy.膜性肾病的未来管理前景。
Clin Kidney J. 2023 Mar 10;16(8):1228-1238. doi: 10.1093/ckj/sfad041. eCollection 2023 Aug.
6
Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment.多发性骨髓瘤患者接种疫苗后抗SARS-CoV-2抗体反应与低CD19+B淋巴细胞计数及抗CD38治疗相关。
Cancers (Basel). 2021 Jul 28;13(15):3800. doi: 10.3390/cancers13153800.
7
Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.接受B细胞清除疗法的抗中性粒细胞胞浆抗体相关性血管炎患者接种新型冠状病毒疫苗后的抗原特异性体液免疫和细胞免疫
Front Immunol. 2022 Jan 28;13:834981. doi: 10.3389/fimmu.2022.834981. eCollection 2022.
8
Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications - A pilot study.抗 CD20 药物治疗多发性硬化症患者对 COVID-19 抗原的回忆反应保持不变 - 一项初步研究。
Mult Scler Relat Disord. 2022 Mar;59:103560. doi: 10.1016/j.msard.2022.103560. Epub 2022 Jan 24.
9
Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma.淋巴细胞减少症和抗CD38定向治疗对多发性骨髓瘤患者初免-加强疫苗接种后血清学SARS-CoV-2反应的影响。
J Clin Med. 2021 Nov 24;10(23):5499. doi: 10.3390/jcm10235499.
10
Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma.多发性骨髓瘤患者对 SARS-CoV-2 mRNA COVID-19 疫苗的临床保护反应较低。
Int J Hematol. 2022 May;115(5):737-747. doi: 10.1007/s12185-022-03300-4. Epub 2022 Feb 21.

引用本文的文献

1
Targeting CD38 in Antibody-Mediated Rejection.在抗体介导的排斥反应中靶向CD38
Transpl Int. 2025 May 15;38:14343. doi: 10.3389/ti.2025.14343. eCollection 2025.
2
Newer B-cell and plasma-cell targeted treatments for rituximab-resistant patients with membranous nephropathy.针对利妥昔单抗耐药的膜性肾病患者的新型B细胞和浆细胞靶向治疗方法。
Clin Kidney J. 2025 Mar 21;18(5):sfaf088. doi: 10.1093/ckj/sfaf088. eCollection 2025 May.
3
Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy.

本文引用的文献

1
SARS-CoV-2 vaccine responses following CD20-depletion treatment in patients with haematological and rheumatological disease: a West Midlands Research Consortium study.在患有血液和风湿性疾病的患者中使用 CD20 耗竭治疗后的 SARS-CoV-2 疫苗反应：西米德兰兹研究联盟研究。
Clin Exp Immunol. 2022 Jan 28;207(1):3-10. doi: 10.1093/cei/uxab018.
2
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma.抗CD38疗法会损害多发性骨髓瘤患者针对新冠病毒α和δ变体的疫苗反应。
Blood. 2022 Feb 10;139(6):942-946. doi: 10.1182/blood.2021013714.
3
Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma.
评估非扎妥单抗在抗磷脂酶A2受体自身抗体阳性原发性膜性肾病中的安全性和有效性的1b/2a期研究
Kidney Int Rep. 2024 Jun 20;9(9):2635-2647. doi: 10.1016/j.ekir.2024.06.018. eCollection 2024 Sep.
淋巴细胞减少症和抗CD38定向治疗对多发性骨髓瘤患者初免-加强疫苗接种后血清学SARS-CoV-2反应的影响。
J Clin Med. 2021 Nov 24;10(23):5499. doi: 10.3390/jcm10235499.
4
Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers.医护人员对BNT162b2 mRNA疫苗的早期血清学反应
Vaccines (Basel). 2021 Aug 16;9(8):913. doi: 10.3390/vaccines9080913.
5
Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.接受免疫抑制治疗的患者对 SARS-CoV-2 疫苗接种的体液和 T 细胞反应。
Ann Rheum Dis. 2021 Oct;80(10):1322-1329. doi: 10.1136/annrheumdis-2021-220626. Epub 2021 Aug 6.
6
Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment.多发性骨髓瘤患者接种疫苗后抗SARS-CoV-2抗体反应与低CD19+B淋巴细胞计数及抗CD38治疗相关。
Cancers (Basel). 2021 Jul 28;13(15):3800. doi: 10.3390/cancers13153800.
7
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment.COVID-19 疫苗接种后骨髓瘤患者的中和抗体反应高度依赖于抗骨髓瘤治疗的类型。
Blood Cancer J. 2021 Aug 2;11(8):138. doi: 10.1038/s41408-021-00530-3.
8
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.在接受利妥昔单抗治疗的患者中接种 SARS-CoV-2 疫苗：B 细胞在 T 细胞介导的免疫存在下促进体液免疫反应。
Ann Rheum Dis. 2021 Oct;80(10):1345-1350. doi: 10.1136/annrheumdis-2021-220781. Epub 2021 Jul 20.